Published in N Engl J Med on May 12, 2011
Computational phenotype discovery using unsupervised feature learning over noisy, sparse, and irregular clinical data. PLoS One (2013) 2.81
Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater (2011) 1.33
Spontaneous tumour lysis syndrome. CMAJ (2012) 1.26
Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies. J Hematol Oncol (2012) 1.23
Uric acid and the kidney. Pediatr Nephrol (2013) 1.12
Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis (2014) 1.11
Cell-selective inhibition of NF-κB signaling improves therapeutic index in a melanoma chemotherapy model. Cancer Discov (2011) 1.08
An unusual presentation of tumor lysis syndrome in a patient with advanced gastric adenocarcinoma: case report and literature review. Case Rep Med (2012) 1.07
Onco-nephrology: AKI in the cancer patient. Clin J Am Soc Nephrol (2012) 1.02
Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses. Oncoimmunology (2013) 1.01
CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). Ther Adv Hematol (2015) 0.95
Anaphylactic reactions to oligosaccharides in red meat: a syndrome in evolution. Clin Mol Allergy (2012) 0.89
The xanthine oxidase inhibitor Febuxostat reduces tissue uric acid content and inhibits injury-induced inflammation in the liver and lung. Eur J Pharmacol (2014) 0.88
Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient. Clin Mol Hepatol (2015) 0.85
Tumor lysis syndrome: A clinical review. World J Crit Care Med (2015) 0.85
Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS One (2013) 0.84
Pseudohyperkalemia without reported haemolysis in a patient with chronic lymphocytic leukaemia. BMJ Case Rep (2012) 0.84
A tumour lysis syndrome in a chemotherapy naïve patient with metastatic pancreatic adenocarcinoma. BMJ Case Rep (2015) 0.83
Tumour lysis syndrome in a patient with intravascular spread from a recurrent epithelial ovarian cancer. BMJ Case Rep (2013) 0.83
Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy. Core Evid (2015) 0.83
Spontaneous Tumor Lysis Syndrome: A Case Report and Critical Evaluation of Current Diagnostic Criteria and Optimal Treatment Regimens. J Investig Med High Impact Case Rep (2015) 0.83
Acute renal failure and type B lactic acidosis as first manifestation of extranodal T-cell lymphoblastic lymphoma. BMJ Case Rep (2014) 0.82
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol (2017) 0.81
Postoperative hyperphosphatemia significantly associates with adverse survival in colorectal cancer patients. J Gastroenterol Hepatol (2013) 0.80
Spontaneous tumour lysis syndrome associated with contrast dye iohexol use in mantle cell lymphoma. BMJ Case Rep (2014) 0.80
Pro-inflammatory effects of uric acid in the gastrointestinal tract. Immunol Invest (2013) 0.80
Hyperphosphatemia during spontaneous tumor lysis syndrome culminate in severe hypophosphatemia at the time of blast crisis of Phneg CML to acute myelomoncytic leukemia. Exp Hematol Oncol (2012) 0.79
Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf (2015) 0.79
Uric Acid Nephrolithiasis: A Systemic Metabolic Disorder. Clin Rev Bone Miner Metab (2011) 0.79
Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model. Mol Ther (2016) 0.78
Acute kidney injury in the perioperative period and in intensive care units (excluding renal replacement therapies). Ann Intensive Care (2016) 0.78
Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. Clin Pharmacol (2014) 0.78
Higher serum phosphorus is associated with catabolic/anabolic imbalance in heart failure. J Cachexia Sarcopenia Muscle (2015) 0.78
The tumor lysis syndrome. N Engl J Med (2011) 0.76
Tumor lysis syndrome in a solid tumor: a case report of a patient with invasive thymoma. Cancer Res Treat (2013) 0.76
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol (2017) 0.76
A Case of Tumor Lysis Syndrome in a Patient with Pancreatic Adenocarcinoma Treated with Low-Dose Gemcitabine. Ochsner J (2015) 0.76
Radiation-Induced Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia. Turk J Haematol (2016) 0.76
Imaging of acute and subacute toxicities of cancer therapy in children. Pediatr Radiol (2015) 0.76
The tumor lysis syndrome. N Engl J Med (2011) 0.75
Tumor lysis syndrome in the emergency department: challenges and solutions. Open Access Emerg Med (2015) 0.75
Tumor lysis syndrome and acute anemia in an African-American man with chronic lymphocytic leukemia. Oxf Med Case Reports (2014) 0.75
Role of host xanthine oxidase in infection due to enteropathogenic and Shiga-toxigenic Escherichia coli. Gut Microbes (2013) 0.75
A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity. J Pharmacol Exp Ther (2017) 0.75
Endoscopic ultrasound-guided ethanol ablation of a large metastatic carcinoid tumor: success with a note of caution. Endosc Int Open (2014) 0.75
Tumor lysis syndrome in an extraskeletal osteosarcoma: a case report and review of the literature. J Med Case Rep (2017) 0.75
Development of tumor lysis syndrome (TLS): A potential risk factor in cancer patients receiving anticancer therapy. Bioinformation (2014) 0.75
Medical management of tumor lysis syndrome, postprocedural pain, and venous thromboembolism following interventional radiology procedures. Semin Intervent Radiol (2015) 0.75
Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience. Oncol Lett (2015) 0.75
Tumor lysis syndrome and primary hepatic malignancy: case presentation and review of the literature. Semin Intervent Radiol (2015) 0.75
Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase. Onco Targets Ther (2017) 0.75
Transcatheter arterial embolization with trisacryl gelatin microspheres (Embosphere(®)) leads to life-threatening tumor lysis syndrome in a rectal carcinoid patient with hepatic metastases. Acta Radiol Short Rep (2012) 0.75
CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside. Oncoimmunology (2016) 0.75
The Safety of available immunotherapy for the treatment of glioblastoma. Expert Opin Drug Saf (2016) 0.75
Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report. J Med Case Rep (2016) 0.75
Hypercalcemia in tumor lysis syndrome. Indian J Hematol Blood Transfus (2013) 0.75
A focused review of the pathogenesis, diagnosis, and management of tumor lysis syndrome for the interventional radiologist. Semin Intervent Radiol (2015) 0.75
Histidine switch controlling pH-dependent protein folding and DNA binding in a transcription factor at the core of synthetic network devices. Mol Biosyst (2016) 0.75
The tumor lysis syndrome. N Engl J Med (2011) 0.75
Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome. Oncol Lett (2014) 0.75
Tumor lysis syndrome in a patient with metastatic colon cancer after treatment with 5-fluorouracil/leucovorin and oxaliplatin: case report and literature review. Cancer Res Treat (2014) 0.75
Tumor Lysis-like Syndrome in Eosinophilic Disease of the Lung: A Case Report and Review of the Literature. Intern Med (2016) 0.75
Steroid-induced tumour lysis syndrome in small-cell lung cancer. Oxf Med Case Reports (2017) 0.75
A Case of Spontaneous Tumor Lysis Syndrome in Malignant Melanoma. World J Oncol (2016) 0.75
Spontaneous Tumor Lysis Syndrome in Small-Cell Lung Cancer: A Rare Complication. World J Oncol (2015) 0.75
Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis. Intern Med (2017) 0.75
Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med (2008) 14.40
Uric acid and cardiovascular risk. N Engl J Med (2008) 12.20
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol (2004) 4.03
Oral phosphate binders in patients with kidney failure. N Engl J Med (2010) 3.42
Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol (2008) 3.34
Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol (2010) 2.89
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum (2008) 2.61
Genetic disorders of renal phosphate transport. N Engl J Med (2010) 2.59
Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica (2008) 2.32
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood (2001) 1.86
A predictive model for the detection of tumor lysis syndrome during AML induction therapy. Leuk Lymphoma (2006) 1.67
Physicochemical aspects of urolithiasis. Kidney Int (1978) 1.62
Fatal tumor lysis syndrome during radiotherapy for non-small-cell lung cancer. J Clin Oncol (2008) 1.62
Could uric acid have a role in acute renal failure? Clin J Am Soc Nephrol (2006) 1.56
Emerging drugs for hyperphosphatemia. Expert Opin Emerg Drugs (2007) 1.55
A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome. Intern Med (2010) 1.54
Urinary xanthine stones--a rare complications of allopurinol therapy. N Engl J Med (1969) 1.45
Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. J Clin Oncol (2001) 1.38
Improving outcomes from acute kidney injury: report of an initiative. Am J Kidney Dis (2007) 1.26
Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am J Kidney Dis (2010) 1.22
Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia (2001) 1.21
A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. Nephrol Dial Transplant (2009) 1.21
Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules. Kidney Int (1998) 1.15
Systemic inflammatory response syndrome and multiple organ dysfunction in patients with acute tumor lysis syndrome. Clinics (Sao Paulo) (2009) 1.13
Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol (2006) 1.12
Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia. Pediatr Blood Cancer (2005) 1.11
Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. World J Gastroenterol (2009) 1.10
Phosphatemic control during acute renal failure: intermittent hemodialysis versus continuous hemodiafiltration. Int J Artif Organs (2001) 1.07
Causes of death in patients with burkitt's lymphoma--the role of supportive care in overall management. East Afr Med J (1974) 1.07
Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest (1977) 1.04
Estimating phosphate removal in haemodialysis: an additional tool to quantify dialysis dose. Nephrol Dial Transplant (2002) 1.04
Management of tumor lysis syndrome: need for evidence-based guidelines. J Clin Oncol (2008) 1.03
Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma. J Clin Oncol (2008) 1.00
A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults. Eur J Haematol (2010) 0.95
Effects of urinary macromolecules on hydroxyapatite crystal formation. J Am Soc Nephrol (2001) 0.94
Features at presentation predict children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome. Cancer (2007) 0.94
Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome. J Oncol Pharm Pract (2010) 0.93
Xanthine urolithiasis. Urology (2006) 0.93
The role of hypercytokinemia in the pathophysiology of tumor lysis syndrome (TLS) and the treatment with continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter (PMMA-CHDF). Transfus Apher Sci (2008) 0.91
Uric acid as inducer of calcium oxalate crystal development. Scand J Urol Nephrol (2007) 0.90
Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia. Clin Adv Hematol Oncol (2009) 0.90
Managing tumor lysis syndrome in 2010. Leuk Lymphoma (2010) 0.90
Rasburicase: future directions in tumor lysis management. Expert Opin Biol Ther (2008) 0.87
Tumor lysis syndrome associated with carboplatin and paclitaxel in a woman with recurrent endometrial cancer. Int J Gynaecol Obstet (2010) 0.86
Pitfalls in predicting tumor lysis syndrome. Leuk Lymphoma (2006) 0.84
Catastrophic tumour lysis syndrome following single dose of imatinib. Eur J Haematol (2008) 0.82
Tumor lysis syndrome in solid tumors. J Clin Oncol (2009) 0.82
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16
Gene expression profiling of pediatric acute myelogenous leukemia. Blood (2004) 3.77
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol (2010) 3.76
CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72
Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet (2009) 3.71
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol (2008) 3.34
NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol (2010) 2.85
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72
Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. Blood (2009) 2.70
Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med (2012) 2.60
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2012) 2.55
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res (2011) 2.52
The Pediatric Cancer Genome Project. Nat Genet (2012) 2.49
Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst (2006) 2.42
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA (2007) 2.38
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood (2010) 2.37
Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet (2009) 2.37
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol (2008) 2.29
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20
A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood (2007) 2.19
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood (2012) 2.14
The feasibility and outcome of nephron-sparing surgery for children with bilateral Wilms tumor. The St Jude Children's Research Hospital experience: 1999-2006. Cancer (2008) 2.08
Outcomes of hematopoietic stem cell transplant patients who received continuous renal replacement therapy in a pediatric oncology intensive care unit. Pediatr Crit Care Med (2010) 2.08
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest (2007) 2.05
Ambulatory blood pressure and increased left ventricular mass in children at risk for hypertension. J Pediatr (2007) 2.00
Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet (2005) 1.94
Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia. JAMA (2002) 1.93
Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer (2005) 1.93
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood (2012) 1.90
Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood (2008) 1.89
Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol (2013) 1.88
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood (2011) 1.88
Changes in bone mineral density in survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer (2006) 1.82
Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst (2013) 1.81
Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet (2003) 1.79
Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood (2008) 1.79
New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2011) 1.78
Adult acute lymphoblastic leukemia: concepts and strategies. Cancer (2010) 1.78
Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. J Clin Oncol (2013) 1.76
Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol (2003) 1.75
Childhood cancer epidemiology in low-income countries. Cancer (2008) 1.74
Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood (2002) 1.74
L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer (2010) 1.69
High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood (2011) 1.68
PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet (2012) 1.66
Smaller white-matter volumes are associated with larger deficits in attention and learning among long-term survivors of acute lymphoblastic leukemia. Cancer (2006) 1.64
Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst (2012) 1.64
Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol (2010) 1.62
Saving the children--improving childhood cancer treatment in developing countries. N Engl J Med (2005) 1.62
An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell (2012) 1.61
Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol (2011) 1.60
Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies. Pediatr Blood Cancer (2011) 1.59
Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell (2005) 1.58
Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA (2004) 1.56
Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood (2007) 1.56
Feasibility and initial effectiveness of home exercise during maintenance therapy for childhood acute lymphoblastic leukemia. Pediatr Phys Ther (2014) 1.53
Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood (2006) 1.52
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol (2011) 1.52
Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood (2007) 1.52
Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood (2003) 1.51
Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol (2010) 1.49
PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet (2014) 1.49
Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. AJNR Am J Neuroradiol (2005) 1.48
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol (2004) 1.48
Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. Clin Lymphoma (2003) 1.48
Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood (2010) 1.47
Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia. Cancer (2007) 1.47
Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer (2008) 1.46
Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest (2005) 1.46
Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet (2013) 1.45
Proxy assessment of quality of life in pediatric clinical trials: application of the Health Utilities Index 3. Qual Life Res (2005) 1.44
The Health Utilities Index 3 invalidated when completed by nurses for pediatric oncology patients. Cancer Nurs (2007) 1.43
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood (2005) 1.42
Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol (2003) 1.41
Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood (2006) 1.41
A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood (2006) 1.40
ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol (2012) 1.39
Lack of benefit of early detection of relapse after completion of therapy for acute lymphoblastic leukemia. Pediatr Blood Cancer (2005) 1.38
In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med (2008) 1.37
A prospective cohort study of late sequelae of pediatric allogeneic hematopoietic stem cell transplantation. Medicine (Baltimore) (2007) 1.37
Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat Med (2011) 1.34
Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma. J Clin Oncol (2007) 1.33
Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol (2014) 1.31
Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol (2012) 1.30
Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood (2002) 1.28
Attention and working memory abilities in children treated for acute lymphoblastic leukemia. Cancer (2010) 1.26
Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer (2003) 1.25
Femoral head osteonecrosis in pediatric and young adult patients with leukemia or lymphoma. J Clin Oncol (2007) 1.22